- Home
- OM vs SLN Comparison
OM vs SLN Comparison
Compare OM & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- SLN
- Stock Information
- Founded
- OM 2003
- SLN 1994
- Country
- OM United States
- SLN United Kingdom
- Employees
- OM 354
- SLN N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- OM Health Care
- SLN Health Care
- Exchange
- OM Nasdaq
- SLN Nasdaq
- Market Cap
- OM 247.1M
- SLN 299.4M
- IPO Year
- OM 2020
- SLN N/A
- Fundamental
- Price
- OM $13.91
- SLN $4.81
- Analyst Decision
- OM Hold
- SLN Buy
- Analyst Count
- OM 1
- SLN 5
- Target Price
- OM $22.00
- SLN $32.60
- AVG Volume (30 Days)
- OM 288.8K
- SLN 61.8K
- Earning Date
- OM 08-06-2025
- SLN 08-07-2025
- Dividend Yield
- OM N/A
- SLN N/A
- EPS Growth
- OM N/A
- SLN N/A
- EPS
- OM N/A
- SLN N/A
- Revenue
- OM $119,304,000.00
- SLN $27,169,000.00
- Revenue This Year
- OM $12.37
- SLN N/A
- Revenue Next Year
- OM $10.52
- SLN N/A
- P/E Ratio
- OM N/A
- SLN N/A
- Revenue Growth
- OM 2.47
- SLN 22.28
- 52 Week Low
- OM $5.85
- SLN $1.97
- 52 Week High
- OM $25.35
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- OM 43.41
- SLN 34.88
- Support Level
- OM $13.60
- SLN $4.91
- Resistance Level
- OM $14.35
- SLN $5.34
- Average True Range (ATR)
- OM 0.60
- SLN 0.48
- MACD
- OM 0.26
- SLN -0.05
- Stochastic Oscillator
- OM 80.09
- SLN 0.71
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.